Venetoclax

MURANO trial: duvelisib plus venetoclax in R/R CLL, SLL and Richter’s Syndrome 2:57
MURANO trial: duvelisib plus venetoclax in R/R CLL, SLL and Richter’s Syndrome
Jennifer Crombie • 8 Dec 2020
Challenges of selecting frontline therapy in CLL 12:15
Challenges of selecting frontline therapy in CLL
Jacqueline Barrientos • 10 Dec 2020
Venetoclax and BEAM followed by ASCT for R/R NHL 4:56
Venetoclax and BEAM followed by ASCT for R/R NHL
Joseph Maakaron • 9 Feb 2021
Biologic and clinical progression in hematological malignancies at ASH 2020 4:36
Biologic and clinical progression in hematological malignancies at ASH 2020
Arnon Nagler • 9 Dec 2020
Venetoclax plus CLAD/LDAC and aza for older AML patients 4:59
Venetoclax plus CLAD/LDAC and aza for older AML patients
Tapan Kadia • 3 Dec 2020
TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax 1:48
TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax
Kunhwa Kim • 17 Dec 2020
Genetic biomarker use in myeloma: Updates from ASH 2020 1:57
Genetic biomarker use in myeloma: Updates from ASH 2020
Simon Harrison • 7 Dec 2020
Cytoreductive therapy is safe and feasible for newly-diagnosed AML 1:21
Cytoreductive therapy is safe and feasible for newly-diagnosed AML
Kunhwa Kim • 17 Dec 2020
Smoldering myeloma: highlights from ASH 2020 2:56
Smoldering myeloma: highlights from ASH 2020
Irene Ghobrial • 16 Dec 2020
allo-SCT improves survival following venetoclax and azacitidine therapy in AML 2:16
allo-SCT improves survival following venetoclax and azacitidine therapy in AML
Daniel Pollyea • 11 Dec 2020
Ianalumab add-on therapy in CLL patients receiving ibrutinib 1:47
Ianalumab add-on therapy in CLL patients receiving ibrutinib
Ian Flinn • 7 Dec 2020
CLL advances: What will we see more of in 2021? 3:54
CLL advances: What will we see more of in 2021?
John Seymour • 7 Dec 2020
Promising therapies on the horizon for MDS 4:26
Promising therapies on the horizon for MDS
Maria Teresa Voso • 29 Jan 2021
Key clinical trials in high-risk and low-risk MDS 1:27
Key clinical trials in high-risk and low-risk MDS
Uwe Platzbecker • 27 Jan 2021
MDS: managing HMA failure 3:32
MDS: managing HMA failure
Valeria Santini • 25 Jan 2021
Novel therapies in the future of MDS treatment 2:43
Novel therapies in the future of MDS treatment
Felicitas Thol • 22 Jan 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals